A5009988073- Dementia and Cognitive Impairment Research
- Cholinesterase and Neurodegenerative Diseases
- Health Systems, Economic Evaluations, Quality of Life
- Alzheimer's disease research and treatments
- Statistical Methods in Clinical Trials
- Computational Drug Discovery Methods
- Neurological Disorders and Treatments
- Pharmaceutical Practices and Patient Outcomes
- Amyotrophic Lateral Sclerosis Research
- Parkinson's Disease Mechanisms and Treatments
- Attention Deficit Hyperactivity Disorder
- Diet and metabolism studies
- Frailty in Older Adults
- Meta-analysis and systematic reviews
- Treatment of Major Depression
- EEG and Brain-Computer Interfaces
- Functional Brain Connectivity Studies
- Biochemical Acid Research Studies
- Health, Environment, Cognitive Aging
- Genetic Neurodegenerative Diseases
- Advanced Causal Inference Techniques
- Pain Management and Placebo Effect
- Bioinformatics and Genomic Networks
- Intimate Partner and Family Violence
- Family Dynamics and Relationships
TetraLogic Pharmaceuticals (United States)
2016-2025
Indiana University – Purdue University Indianapolis
2023
Eli Lilly (United States)
2023
Purdue University West Lafayette
2023
Alzheimer's Drug Discovery Foundation
2021
Global Alzheimer's Platform Foundation
2021
Hendrix Genetics (Canada)
2019
Prothena (United States)
2017
University of Miami
2017
Roche (United Kingdom)
2017
Sodium phenylbutyrate and taurursodiol have been found to reduce neuronal death in experimental models. The efficacy safety of a combination the two compounds persons with amyotrophic lateral sclerosis (ALS) are not known.
Nutrition is an important modifiable risk factor in Alzheimer's disease. Previous trials of the multinutrient Fortasyn Connect showed benefits mild disease dementia. LipiDiDiet investigated effects on cognition and related measures prodromal Here, we report 24-month results trial.LipiDiDiet was a randomised, controlled, double-blind, parallel-group, multicentre trial (11 sites Finland, Germany, Netherlands, Sweden), with optional 12-month double-blind extensions. The enrolled individuals...
Abstract An orally administered, fixed‐dose coformulation of sodium phenylbutyrate‐taurursodiol (PB‐TURSO) significantly slowed functional decline in a randomized, placebo‐controlled, phase 2 trial ALS (CENTAUR). Herein we report results long‐term survival analysis participants CENTAUR. In CENTAUR, adults with were randomized 2:1 to PB‐TURSO or placebo. Participants completing the 6‐month (24‐week) eligible receive open‐label extension. all‐cause mortality (35‐month maximum follow‐up...
Aducanumab (Aduhelm) is approved in the United States for treatment of patients with mild cognitive impairment due to Alzheimer's disease or AD dementia. Appropriate Use Recommendations (AURs) have been published and helped guide best practices use aducanumab. As real-world has occurred more information accrued, AURs require refinement. We update better inform appropriate patient selection improve shared decision-making, safety monitoring, risk mitigation treated patients. Based on evolving...
ABSTRACT Staling over a 120‐hr period was compared in gluten‐free rice bread, low‐protein starch and two gluten‐containing breads (standard wheat added‐protein wheat) using quantitative descriptive analysis (QDA), critical stress values obtained by mechanical compression testing, scanning electron microscopy (SEM). The bread had the highest QDA scores for both moistness overall freshness, whereas lowest attributes. Differences demonstrated that greatest resistance to collapse, indicating...
<b>Airway ciliary function analysis underpins PCD diagnostics and <i>ex vivo</i>/<i>in vitro</i> mucociliary clearance studies. It is an important measure of airway culture model integrity in health after microbial/viral infections or drug therapies.</b>https://bit.ly/3EXsG5J
Background This study reports the findings of first large-scale Phase III investigator-driven clinical trial to slow rate cognitive decline in Alzheimer disease with a dihydropyridine (DHP) calcium channel blocker, nilvadipine. Nilvadipine, licensed treat hypertension, reduces amyloid production, increases regional cerebral blood flow, and has demonstrated anti-inflammatory anti-tau activity preclinical studies, properties that could have disease-modifying effects for disease. We aimed...
Abstract An international task force of investigators from academia, industry, nonprofit foundations, and regulatory agencies met in Monte Carlo, Monaco, on October 31, 2012, to review lessons learned the recent bapineuzumab solanezumab trials, incorporate insights gained these trials into future clinical studies. Although there is broad consensus that Alzheimer's disease (AD) should be treated during its earliest stages, concept secondary prevention has evolved described more accurately as...
<h3>Background</h3> Development of new therapies for Alzheimer9s disease (AD) is increasingly focused on more mildly affected populations, and requires assessment outcome strategies. Patients in early stages AD have mild cognitive decline no, or limited, functional impairment. To respond to these challenges, we developed a measurement approach based established scale items that exhibited change previous amnestic Mild Cognitive Impairment (aMCI) trials. <h3>Methods</h3> Partial least squares...
Autosomal-dominant Alzheimer's disease (ADAD) represents a crucial population for identifying prevention strategies that might modify course cognitively unimpaired individuals at high imminent risk developing symptoms due to (AD), is, who have "preclinical" AD. Crenezumab is an antiamyloid monoclonal antibody binds monomeric and aggregated forms of amyloid β, with highest affinity oligomers; it in development early stages sporadic AD ADAD.
There is growing interest in the evaluation of preclinical Alzheimer's disease (AD) treatments. As a result, there need to identify cognitive composite that sensitive track AD decline be used as primary endpoint treatment trials.
Abstract Introduction This phase 2b/3 trial examined the effects of plasma exchange (PE) in patients with mild‐to‐moderate Alzheimer's disease (AD). Methods Three hundred forty‐seven (496 screened) were randomized (1:1:1:1) into three PE treatment arms different doses albumin and intravenous immunoglobulin replacement (6‐week period weekly conventional followed by a 12‐month monthly low‐volume PE), placebo (sham). Results PE‐treated performed significantly better than for co‐primary...
The LipiDiDiet trial investigates the effects of specific multinutrient combination Fortasyn Connect on cognition and related measures in prodromal Alzheimer's disease (AD). Based previous results we hypothesized that benefits increase with long-term intervention.In this randomized, double-blind, placebo-controlled trial, 311 people AD were recruited using International Working Group-1 criteria assigned to active product (125 mL once-a-day drink) or an isocaloric, same tasting, placebo...
Like virtually all age-related chronic diseases, late-onset Alzheimer's disease (AD) develops over an extended preclinical period and is associated with modifiable lifestyle environmental factors. We hypothesize that multimodal interventions address many risk factors simultaneously are individually tailored to patients may help reduce AD risk. describe a novel clinical methodology used evaluate treat at two Prevention Clinics. The framework applies evidence-based principles of precision...
BackgroundCardiosphere-derived cells (CDCs) ameliorate skeletal and cardiac muscle deterioration in experimental models of Duchenne muscular dystrophy. The HOPE-2 trial examined the safety efficacy sequential intravenous infusions human allogeneic CDCs late-stage dystrophy.MethodsIn this multicentre, randomised, double-blind, placebo-controlled, phase 2 trial, patients with dystrophy, aged 10 years or older moderate upper limb impairment, were enrolled at seven centres USA. Patients randomly...
Coformulated sodium phenylbutyrate/taurursodiol (PB/TURSO) was shown to prolong survival and slow functional decline in amyotrophic lateral sclerosis (ALS).
Abstract Introduction/Aims Trials incorporating placebo‐to‐active treatment crossover are encouraged in fatal conditions like amyotrophic lateral sclerosis (ALS) but may underestimate active survival benefit. Here, we apply methods for modeling without crossover, including the rank‐preserving structural failure time model (RPSFTM), to data from CENTAUR trial of sodium phenylbutyrate and taurursodiol (PB TURSO) ALS both randomized placebo‐controlled open‐label extension (OLE) phases. Methods...
Abstract A crucial aspect of any clinical trial is using the right outcome measure to assess treatment efficacy. Compared rapidly evolved understanding and measurement pathophysiology in preclinical early symptomatic stages Alzheimer's disease (AD), relatively less progress has been made evolution assessments (COAs) for those stages. The current paper aims provide a benchmark design evaluation COAs use AD trials. We discuss lessons learned on capturing cognitive changes predementia AD,...
Anti-amyloid vaccines may offer a convenient, affordable, and accessible means of preventing treating Alzheimer's disease. UB-311 is an anti-amyloid-β active immunotherapeutic vaccine shown to be well-tolerated have durable antibody response in phase 1 trial. This 2a study assessed the safety, immunogenicity, preliminary efficacy participants with mild disease.A 78-week, randomised, double-blind, placebo-controlled, parallel-group, multicentre, was conducted Taiwan. Participants were...
Background Alzheimer’s Disease (AD) is a multifactorial, progressive neurodegenerative disease that disrupts synaptic and neuronal activity network oscillations. It characterized by loss, brain atrophy decline in cognitive functional abilities. Cognito’s Evoked Gamma Therapy System provides an innovative approach for AD inducing EEG-verified gamma oscillations through sensory stimulation. Prior research has shown promising disease-modifying effects experimental models. The present study...
To evaluate the safety and tolerability pharmacokinetic properties of R-flurbiprofen (Tarenflurbil) in normal elderly individuals to determine effect drug on amyloid beta 42 (Aβ42) levels, we conducted a double-blind, placebo-controlled study 48 healthy subjects aged 55 80. Three successive cohorts were randomized doses 400, 800, or 1600 mg/d, placebo, given as 2 divided for 21 days. Blood cerebrospinal fluid collected studies measurement Aβ levels at baseline day 21. was well-tolerated all...